The non‐haematopoietic biological effects of erythropoietin
- 6 March 2008
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 141 (1), 14-31
- https://doi.org/10.1111/j.1365-2141.2008.07014.x
Abstract
In the haematopoietic system, the principal function of erythropoietin (Epo) is the regulation of red blood cell production, mediated by its specific cell surface receptor (EpoR). Following the cloning of the Epo gene (EPO) and characterization of the selective haematopoietic action of Epo in erythroid lineage cells, recombinant Epo forms (epoetin-alfa, epoetin-beta and the long-acting analogue darbepoetin-alfa) have been widely used for treatment of anaemia in chronic kidney disease and chemotherapy-induced anaemia in cancer patients. Ubiquitous EpoR expression in non-erythroid cells has been associated with the discovery of diverse biological functions for Epo in non-haematopoietic tissues. During development, Epo-EpoR signalling is required not only for fetal liver erythropoiesis, but also for embryonic angiogenesis and brain development. A series of recent studies suggest that endogenous Epo-EpoR signalling contributes to wound healing responses, physiological and pathological angiogenesis, and the body's innate response to injury in the brain and heart. Epo and its novel derivatives have emerged as major tissue-protective cytokines that are being investigated in the first human studies involving neurological and cardiovascular diseases. This review focuses on the scientific evidence documenting the biological effects of Epo in non-haematopoietic tissues and discusses potential future applications of Epo and its derivatives in the clinic.Keywords
This publication has 108 references indexed in Scilit:
- Post‐ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemiaBritish Journal of Pharmacology, 2007
- Erythropoietin involves the phosphatidylinositol 3‐kinase pathway, 14‐3‐3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrityBritish Journal of Pharmacology, 2007
- Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosisBiochemical and Biophysical Research Communications, 2007
- Acute postnatal ablation of Hif-2 α results in anemiaProceedings of the National Academy of Sciences, 2007
- Erythropoietin (EPO) — EPO-receptor signaling improves early endochondral ossification and mechanical strength in fracture healingLife Sciences, 2007
- Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditisBiochemical and Biophysical Research Communications, 2006
- Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activitiesProceedings of the National Academy of Sciences of the United States of America, 2006
- A novel endogenous erythropoietin mediated pathway prevents axonal degenerationAnnals of Neurology, 2004
- Erythropoietin Prevents Place Navigation Disability and Cortical Infarction in Rats with Permanent Occlusion of the Middle Cerebral ArteryBiochemical and Biophysical Research Communications, 1998
- Erythropoietin Induces Tyrosine Phosphorylation of the β Chain of the GM-CSF ReceptorBiochemical and Biophysical Research Communications, 1995